Quick Links GLP2 + Cagrilintide Blend Peptide The Four-Pathway Metabolic Research Compound Also known as: GLP3/Cagri Blend, Lean Blend, CagriGLP3 Why Researchers Choose GLP3 + Cagrilintide Blend Peptide Unlike single or dual-pathway peptides, this blend targets four distinct metabolic receptorscombining GLP3s triple incretin action (GLP-1, GIP, and glucagon receptors) with Cagrilintides amylin pathway activation
To avoid enzymatic cleavage by DPP-4, the N-terminal penultimate amino acid has been replaced with other amino acids (albiglutide, dulaglutide, and semaglutide) or added with a fatty acid moiety (liraglutide and semaglutide), so that albumin binds and shields the enzymatic attack site
Route of Administration: How you deliver the KLOW peptide matters immensely
Any peptide that increases serotonin, dopamine, or norepinephrine availability can precipitate serotonin syndrome
We believe that the mechanistic pathways uncovered here have potential for impact in the clinical context of IRI, for which no approved therapies currently exist